Press Releases

June 17, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all evaluable
April 16, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago   ORR (by IWG) of 100% in all
October 10, 2016 — BOSTON, MA., and STOCKHOLM, SWEDEN, October 10, 2016  – Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the